Bessemer Group Inc. Purchases 272,187 Shares of Eli Lilly and Company $LLY

Bessemer Group Inc. lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 46.2% during the 1st quarter, Holdings Channel.com reports. The firm owned 860,704 shares of the company’s stock after buying an additional 272,187 shares during the period. Eli Lilly and Company makes up about 1.2% of Bessemer Group Inc.’s investment portfolio, making the stock its 11th largest position. Bessemer Group Inc.’s holdings in Eli Lilly and Company were worth $791,652,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. increased its stake in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares during the period. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $356,000. Finally, Nebula Research & Development LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at about $749,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley strengthens its neuroscience pipeline and adds exposure to treatment-resistant depression and other mental health markets. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Several Wall Street notes also turned more bullish on Lilly, with UBS and other firms raising price targets and pointing to continued momentum in Lilly’s GLP-1 and broader pipeline. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Neutral Sentiment: The acquisition comes amid mixed competitive headlines in obesity drugs, including Novo Nordisk’s oral Wegovy approval in Europe, which highlights the rivalry in Lilly’s core growth areas. Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
• Negative Sentiment: Some commentary suggests Lilly is paying a rich price for a still-early-stage psychedelic asset, which may raise questions about clinical risk and return on investment if the programs do not deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,172.50 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock’s fifty day moving average is $1,114.27 and its two-hundred day moving average is $1,035.81. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 41.65, a price-to-earnings-growth ratio of 1.45 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the company earned $3.34 EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.